FR2883180B1 - Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre - Google Patents

Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre

Info

Publication number
FR2883180B1
FR2883180B1 FR0502696A FR0502696A FR2883180B1 FR 2883180 B1 FR2883180 B1 FR 2883180B1 FR 0502696 A FR0502696 A FR 0502696A FR 0502696 A FR0502696 A FR 0502696A FR 2883180 B1 FR2883180 B1 FR 2883180B1
Authority
FR
France
Prior art keywords
medicament
preparation
treatment
balance disorders
acetyl leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0502696A
Other languages
English (en)
French (fr)
Other versions
FR2883180A1 (fr
Inventor
Christophe Przybylski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0502696A priority Critical patent/FR2883180B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to JP2008501329A priority patent/JP2008533102A/ja
Priority to PCT/EP2006/060841 priority patent/WO2006097527A1/fr
Priority to US11/886,419 priority patent/US20080108702A1/en
Priority to CA002601101A priority patent/CA2601101A1/fr
Priority to EP06725137A priority patent/EP1865943A1/fr
Publication of FR2883180A1 publication Critical patent/FR2883180A1/fr
Application granted granted Critical
Publication of FR2883180B1 publication Critical patent/FR2883180B1/fr
Priority to JP2013081360A priority patent/JP2013173759A/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0502696A 2005-03-18 2005-03-18 Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre Expired - Lifetime FR2883180B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0502696A FR2883180B1 (fr) 2005-03-18 2005-03-18 Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
PCT/EP2006/060841 WO2006097527A1 (fr) 2005-03-18 2006-03-17 Utilisation de l'acétyl-leucine pour la préparation d'un médicament destiné au traitement de troubles de l'équilibre
US11/886,419 US20080108702A1 (en) 2005-03-18 2006-03-17 Use of Acetyl-Leucine for Preparing a Drug for Treating Balance Disorders
CA002601101A CA2601101A1 (fr) 2005-03-18 2006-03-17 Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
JP2008501329A JP2008533102A (ja) 2005-03-18 2006-03-17 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用
EP06725137A EP1865943A1 (fr) 2005-03-18 2006-03-17 Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
JP2013081360A JP2013173759A (ja) 2005-03-18 2013-04-09 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0502696A FR2883180B1 (fr) 2005-03-18 2005-03-18 Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre

Publications (2)

Publication Number Publication Date
FR2883180A1 FR2883180A1 (fr) 2006-09-22
FR2883180B1 true FR2883180B1 (fr) 2007-05-25

Family

ID=35134794

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0502696A Expired - Lifetime FR2883180B1 (fr) 2005-03-18 2005-03-18 Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre

Country Status (6)

Country Link
US (1) US20080108702A1 (https=)
EP (1) EP1865943A1 (https=)
JP (2) JP2008533102A (https=)
CA (1) CA2601101A1 (https=)
FR (1) FR2883180B1 (https=)
WO (1) WO2006097527A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
ES2994242T3 (en) * 2016-04-19 2025-02-05 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
DK3359146T3 (en) * 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3455638B2 (ja) * 1996-02-23 2003-10-14 株式会社モリタ製作所 平衡機能検査装置
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
ID29095A (id) * 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress

Also Published As

Publication number Publication date
JP2008533102A (ja) 2008-08-21
EP1865943A1 (fr) 2007-12-19
WO2006097527A1 (fr) 2006-09-21
CA2601101A1 (fr) 2006-09-21
FR2883180A1 (fr) 2006-09-22
JP2013173759A (ja) 2013-09-05
US20080108702A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
EP2056848A4 (en) USE OF EXTRACTS FOR THE TREATMENT OF VIRAL DISEASES
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
FR2867778B1 (fr) Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
EP1601251A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
EP1951272A4 (en) USE OF LACTOBACILLUS FOR THE TREATMENT OF VIRUS INFECTIONS
EP1551369A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES
EP1865976A4 (en) USE OF A NATRIURETIC PEPTIDE FOR THE TREATMENT OF HEART FAILURES
EP1461323A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
EP2260851A4 (en) USE OF PENTACYCLIC TRITERPEN FOR THE PREPARATION OF A PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF MULTIPLE SCLEROSIS
EP2307011A4 (en) USE OF ISOINDOLENE FOR THE TREATMENT OF NEURO BEHAVIORAL DISORDERS
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
EP2120930A4 (en) USE OF CHROMIHISTIDINATE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
FR13C0044I2 (fr) Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
EP1556085A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
EP1750513A4 (en) USE OF GPCR54 LIGANDS FOR THE TREATMENT OF BARRENESS
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
EP2219447A4 (en) S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF UTERUS HYPERCONTACTILITY DISORDERS
FR2883180B1 (fr) Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
EP1931779A4 (en) NEW PEPTIDES FOR THE TREATMENT AND PREVENTION OF IMMUNE-RELATED DISORDERS, INCLUDING TREATMENT AND PREVENTION BY MODULATION OF BORN IMMUNITY
MA29720B1 (fr) Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
EP1952811A4 (en) USE OF ERIOCALYXIN B IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LEUKEMIA

Legal Events

Date Code Title Description
LIMR Limitation of claims
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20